An upcoming episode of RedChip Small Stocks, Big Money show, a Bloomberg TV sponsored program, will feature exclusive interviews with top officials from Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG). The episode is scheduled to be broadcasted on Saturday, July 19, at 7 p.m. Eastern Time.
On this program, George Ng, Processa Pharmaceuticals’ CEO, will delineate the company’s approach towards revolutionizing cancer treatment drug development. Taking known chemotherapy agents, Processa is working towards creating safer and more efficient Next Generation Cancer (NGC) therapies.
The company head will spotlight Processa’s primary asset, PCS6422 (NGC-Cap), currently involved in a Phase 2 trial recruiting patients with metastatic breast cancer. Ng will also outline how Processa’s Regulatory Science Approach is instrumental in producing superior tumor-targeting medicines having significantly lower toxicity levels.
Additionally, Ng will speak about the recent capital boost of $7 million the company has received, together with the value-enhancing partnership formed with Intact Therapeutics for PCS12852. Furthermore, he will delve into the strategic reassessment of the company’s pipeline intending to prioritize assets having solid commercial viability and regulatory promise.
Processa Pharmaceuticals, with its imminent catalysts and a model that is capital-efficient, presents a notable microcap investment opportunity in the oncology sector for insightful investors.
In the same episode, Vin Singh, the CEO of BullFrog AI, will also share insight into how BullFrog is revolutionizing the drug development process using its enterprise-scale AI platform named BullFrog Data Networks, powered by the proprietary bfLEAP engine.
Singh will discuss how their unique multimodal, causal AI technology allows companies in the life sciences domain to identify new drug targets, optimize clinical trials, and repurpose existing treatments, resulting in a significant reduction in both development costs and timelines.
Specific emphasis will be laid upon BullFrog’s recent commercial growth through a strategic alliance formed with Sygnature Discovery, which is anticipated to result in revenue generation worth up to $30 million by 2028. Singh will also shed light on exclusive research collaborations with esteemed institutions such as the J. Craig Venter Institute and the Lieber Institute.
With a scalable model that can be deployed via the cloud and a business model strategically designed for recurring software revenue, BullFrog AI is providing investors with a distinct investment opportunity situated at the crossroads of biotechnology and pioneering artificial intelligence.
Processa Pharmaceuticals is a clinical-stage pharmaceutical enterprise passionately focusing on the creation of safety-enhanced and more efficacious Next Generation Cancer (NGC) drugs.
Processa’s NGC drugs are revamped versions of existing FDA-approved oncology treatments, which cause alterations in the metabolism and distribution of these treatments while conserving the existing cancer cell termination mechanisms.
Processa, standing on the pillars of its innovative oncology pipeline, effective active cancer molecules, and Regulatory Science Approach, is dedicatedly nurturing its objective to create superior therapeutic options. These options are projected to offer improved tolerability and are geared towards cancer patients, all while traversing an efficient regulatory path.
BullFrog AI employs Artificial Intelligence and machine learning to propel advancements in the discovery and development of drugs. The company leverages causal AI bundled with its unique bfLEAP platform to parse complex biological data, with an aim to expedite therapeutics development and diminish failure rates in clinical trials.
By aligning itself through partnerships with top-notch research institutions, BullFrog AI is exploring previously uncharted avenues in the efficient and accurate development and testing of potential therapeutics.
The post Exclusive Reveal: How Processa Pharmaceuticals & BullFrog AI Revolutionize Oncology and AI Drug Development appeared first on Real News Now.
About Author
